NeuroSense Therapeutics Ltd

1
NAS:NRSN (Israel)  
$ 1.23 -0.03 (-2.38%) 08:09 PM EST
At Loss
Market Cap:
$ 21.32M
Enterprise V:
$ 19.34M
Volume:
42.07K
Avg Vol (2M):
316.61K
Volume:
42.07K
At Loss
Avg Vol (2M):
316.61K

Business Description

Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Name Current Vs Industry Vs History
Cash-To-Debt 18.59
Equity-to-Asset -0.59
Debt-to-Equity -0.08
Debt-to-EBITDA -0.01
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -47
3-Year EPS without NRI Growth Rate -56.2
3-Year FCF Growth Rate -113.4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 15.03
9-Day RSI 25.69
14-Day RSI 33.61
6-1 Month Momentum % 260.55
12-1 Month Momentum % -15.42

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.84
Quick Ratio 0.84
Cash Ratio 0.76

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12
Shareholder Yield % 0.37
Name Current Vs Industry Vs History
ROE % -1152.67
ROA % -191.35
ROIC % -3014.96
ROC (Joel Greenblatt) % -4077.06
ROCE % -337.74

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -1.72
EV-to-EBITDA -1.72
EV-to-FCF -2.28
Earnings Yield (Greenblatt) % -58.14
FCF Yield % -39.78